Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis

Authors McGregor JC, Allen GP, Bearden DT

Published 10 October 2008 Volume 2008:4(5) Pages 843—853

DOI https://doi.org/10.2147/TCRM.S3426

Review by Single-blind

Peer reviewer comments 2

Jessina C McGregor, George P Allen, David T Bearden

Oregon State University College of Pharmacy, Portland, OR, USA

Abstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specific patient sub-populations.

Keywords: urinary tract infection, pyelonephritis, levofloxacin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Risk factors for primary open-angle glaucoma in Japanese subjects attending community health screenings

Ishikawa M, Sawada Y, Sato N, Yoshitomi T

Clinical Ophthalmology 2011, 5:1531-1537

Published Date: 20 October 2011

Treatment of macular edema due to retinal vein occlusions

Channa R, Smith M, Campochiaro P

Clinical Ophthalmology 2011, 5:705-713

Published Date: 24 May 2011

Overriding of the preseptal orbicularis oculi muscle in Caucasian cadavers

Hirohiko Kakizaki, Weng Onn Chan, Yasuhiro Takahashi, Dinesh Selva

Clinical Ophthalmology 2009, 3:243-246

Published Date: 10 March 2009

Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication?

Tarsila CR Ribeiro, Julio MF Chebli, Mario Kondo, Pedro Duarte Gaburri, Liliana Andrade Chebli, Ana Cristina Amaral Feldner

Therapeutics and Clinical Risk Management 2008, 4:919-925

Published Date: 10 October 2008

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Debra L Breneman, Timothy J Storer, John C Breneman, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:1135-1141

Published Date: 10 October 2008

Multi-targeted approach in the treatment of thyroid cancer

Scott N Pinchot, Rebecca S Sippel, Herbert Chen

Therapeutics and Clinical Risk Management 2008, 4:935-947

Published Date: 10 October 2008

Evaluation of extended and continuous use oral contraceptives

Kristen Page Wright, Julia V Johnson

Therapeutics and Clinical Risk Management 2008, 4:905-911

Published Date: 10 October 2008

A young man with acute dilated cardiomyopathy associated with methylphenidate

Tor-Bjarne Nymark, A Hovland, H Bjørnstad, E W Nielsen

Vascular Health and Risk Management 2008, 4:477-479

Published Date: 11 April 2008